Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Luckily for you, our job at StockStory is to help you avoid short-term fads by pointing you toward high-quality businesses that can generate sustainable long-term growth. On that note, here are three growth stocks expanding their competitive advantages.
Rocket Lab (RKLB)
One-Year Revenue Growth: +45.8%
Becoming the first private company in the Southern Hemisphere to reach space, Rocket Lab (NASDAQ:RKLB) offers rockets designed for launching small satellites.
Why Do We Love RKLB?
- Impressive 55.1% annual revenue growth over the last two years indicates it’s winning market share this cycle
- Operating margin expanded by 111.4 percentage points over the last five years as it scaled and became more efficient
- Cash-burning tendencies have improved over the last five years, showing it could become financially independent one day
Rocket Lab is trading at $64.16 per share, or 39.9x forward price-to-sales. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.
Happen Bank (HAPN)
One-Year Revenue Growth: +18.4%
Pioneering peer-to-peer lending in the US before evolving into a digital bank, Happen Bank (NYSE:HAPN) operates a marketplace that connects borrowers with lenders, offering personal loans, auto refinancing, and banking services.
Why Will HAPN Outperform?
- Impressive 18.1% annual revenue growth over the last five years indicates it’s winning market share this cycle
- Additional sales over the last two years increased its profitability as the 108% annual growth in its earnings per share outpaced its revenue
- Adequate return on equity shows management makes decent investment decisions
At $19.10 per share, Happen Bank trades at 9.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
Halozyme Therapeutics (HALO)
One-Year Revenue Growth: +39.1%
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ:HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Why Are We Fans of HALO?
- Market share has increased this cycle as its 32.2% annual revenue growth over the last two years was exceptional
- Earnings per share grew by 28.7% annually over the last five years and trumped its peers
- Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends
Halozyme Therapeutics’s stock price of $82.57 implies a valuation ratio of 9.4x forward P/E. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.